What to Do If Your HbA1c Is Elevated Despite Normal Blood Glucose Levels

When a patient presents with normal fasting and postprandial blood glucose levels but an elevated hemoglobin A1c (HbA1c), clinicians must consider several physiological, technical, and pathological explanations—rather than assuming early or undiagnosed diabetes. HbA1c reflects average glycemia over approximately 120 days, corresponding to the lifespan of red blood cells, and is influenced not only by glucose concentration but also by erythrocyte turnover, hemoglobin variants, and assay methodology.

Common non-diabetic causes include chronic kidney disease, iron deficiency anemia, vitamin B12 or folate deficiency, and conditions associated with increased red blood cell turnover—such as hemolytic anemias, recent blood transfusions, or splenomegaly. In these settings, shortened erythrocyte survival leads to artificially low HbA1c values; conversely, conditions that prolong red blood cell lifespan—like hyposplenism or certain chronic liver diseases—may yield spuriously elevated HbA1c despite normoglycemia.

Hemoglobinopathies—including HbS, HbC, HbE, and some thalassemia traits—can interfere with many HbA1c assays, particularly those based on ion-exchange high-performance liquid chromatography (HPLC) or immunoassay platforms. Such interferences may produce falsely high or low results depending on the variant and assay used. Laboratories should employ HbA1c methods certified by the National Glycohemoglobin Standardization Program (NGSP) and flag potential interferences when abnormal hemoglobin patterns are detected.

Clinical evaluation should begin with a thorough history—including medication use (e.g., opioids, antiretrovirals, or dapsone), recent transfusions, symptoms of anemia or chronic inflammation—and targeted laboratory testing: complete blood count with peripheral smear, reticulocyte count, serum ferritin, iron studies, vitamin B12, folate, renal function tests, and, if indicated, hemoglobin electrophoresis or genetic testing for hemoglobin variants.

In the absence of confounding factors, persistently elevated HbA1c with confirmed normoglycemia warrants repeat testing using an alternative, NGSP-aligned method and consideration of continuous glucose monitoring (CGM) to assess for unrecognized glycemic excursions—particularly postprandial hyperglycemia or nocturnal hypoglycemia—that may not be captured by standard point-of-care glucose measurements.

Management hinges on identifying and addressing the underlying cause—not lowering HbA1c per se. For example, correcting iron deficiency may normalize HbA1c without altering glycemic status; similarly, optimizing renal replacement therapy in dialysis patients can improve assay reliability. Clinicians should avoid initiating antihyperglycemic therapy solely on the basis of discordant HbA1c in the setting of repeatedly normal glucose values.